A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer
Christopher G. Willett, Dan G. Duda(Harvard University), Gregory Y. Lauwers(Moffitt Cancer Center), Christopher R. Mantyh(General Marble (Greece)), Mira Shah(Duke Medical Center), Paul C. Shellito(Harvard University), Marek Ancukiewicz(Bridge University), Martin Poleski(Duke Medical Center), Brian G. Czito(Harvard University), Madeline Carroll(Rush University Medical Center), Rex C. Bentley(Duke University), Daniel C. Chung(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Douglas S. Tyler(University of North Carolina at Chapel Hill), Hiroshi Fujita(Massachusetts General Hospital)
Cited by 54
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k
The Chromosomal Instability Pathway in Colon Cancer
|Gastroenterology|2010|932